Review



human rhodopsin based optogenetic gene therapy  (Acucela Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Acucela Inc human rhodopsin based optogenetic gene therapy
    Comparison of the light sensitivities of natural and artificial photoreceptor systems. Rod and cone photoreceptor sensitivities and melanopsin-expressing retinal ganglion cell sensitivity are compared with those of halorhodopsin (NpHR), wild-type channelrhodopsin 2 (ChR2), and vertebrate rhodopsin installed in various cell types. Light sensitivities are given in photons/cm2 s The wavelengths for the respective therapeutic approaches are color-coded and indicated as numbers in white. All <t>optogenetic</t> channel light sensitivities are based on in vitro retinal whole-mount recordings from retinal ganglion cells (Figure modified from [27])
    Human Rhodopsin Based Optogenetic Gene Therapy, supplied by Acucela Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+rhodopsin+based+optogenetic+gene+therapy/human+rhodopsin+based+optogenetic+gene+therapy/pmc07307607-50-6-1
    Average 90 stars, based on 1 article reviews
    human rhodopsin based optogenetic gene therapy - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin"

    Article Title: Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin

    Journal: Methods in molecular biology (Clifton, N.J.)

    doi: 10.1007/978-1-4939-7522-8_12

    Comparison of the light sensitivities of natural and artificial photoreceptor systems. Rod and cone photoreceptor sensitivities and melanopsin-expressing retinal ganglion cell sensitivity are compared with those of halorhodopsin (NpHR), wild-type channelrhodopsin 2 (ChR2), and vertebrate rhodopsin installed in various cell types. Light sensitivities are given in photons/cm2 s The wavelengths for the respective therapeutic approaches are color-coded and indicated as numbers in white. All optogenetic channel light sensitivities are based on in vitro retinal whole-mount recordings from retinal ganglion cells (Figure modified from [27])
    Figure Legend Snippet: Comparison of the light sensitivities of natural and artificial photoreceptor systems. Rod and cone photoreceptor sensitivities and melanopsin-expressing retinal ganglion cell sensitivity are compared with those of halorhodopsin (NpHR), wild-type channelrhodopsin 2 (ChR2), and vertebrate rhodopsin installed in various cell types. Light sensitivities are given in photons/cm2 s The wavelengths for the respective therapeutic approaches are color-coded and indicated as numbers in white. All optogenetic channel light sensitivities are based on in vitro retinal whole-mount recordings from retinal ganglion cells (Figure modified from [27])

    Techniques Used: Comparison, Expressing, In Vitro, Modification

    Related Articles

    Comparison:

    Article Title: Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin
    Article Snippet: carefully regulated so as to not saturate the cell response, which could cause failure of the cells to follow high frequency stimulation [ 18 , 19 ]. .. Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [ 20 ] for treatment of RP from the Univ. of Manchester [ 21 ], which promises to have higher sensitivity than ChR2 variants. .. In their study, AAV-mediated expression of rhodopsin into both RGCs and inner nuclear layer neurons generated reproducible responses to light pulses a

    Article Title: Retinal Gene Therapy
    Article Snippet: be carefully regulated so as to not saturate the cell response, which could cause failure of the cells to follow high frequency stimulation [18, 19]. .. Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [20] for treatment of RP from the Univ. of Manchester [21], which promises to have higher sensitivity than ChR2 variants. .. In their study, AAV-mediated expression of rhodopsin into both RGCs and inner nuclear layer neurons generated reproducible responses to light pulses a

    Expressing:

    Article Title: Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin
    Article Snippet: carefully regulated so as to not saturate the cell response, which could cause failure of the cells to follow high frequency stimulation [ 18 , 19 ]. .. Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [ 20 ] for treatment of RP from the Univ. of Manchester [ 21 ], which promises to have higher sensitivity than ChR2 variants. .. In their study, AAV-mediated expression of rhodopsin into both RGCs and inner nuclear layer neurons generated reproducible responses to light pulses a

    Article Title: Retinal Gene Therapy
    Article Snippet: be carefully regulated so as to not saturate the cell response, which could cause failure of the cells to follow high frequency stimulation [18, 19]. .. Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [20] for treatment of RP from the Univ. of Manchester [21], which promises to have higher sensitivity than ChR2 variants. .. In their study, AAV-mediated expression of rhodopsin into both RGCs and inner nuclear layer neurons generated reproducible responses to light pulses a

    In Vitro:

    Article Title: Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin
    Article Snippet: carefully regulated so as to not saturate the cell response, which could cause failure of the cells to follow high frequency stimulation [ 18 , 19 ]. .. Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [ 20 ] for treatment of RP from the Univ. of Manchester [ 21 ], which promises to have higher sensitivity than ChR2 variants. .. In their study, AAV-mediated expression of rhodopsin into both RGCs and inner nuclear layer neurons generated reproducible responses to light pulses a

    Article Title: Retinal Gene Therapy
    Article Snippet: be carefully regulated so as to not saturate the cell response, which could cause failure of the cells to follow high frequency stimulation [18, 19]. .. Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [20] for treatment of RP from the Univ. of Manchester [21], which promises to have higher sensitivity than ChR2 variants. .. In their study, AAV-mediated expression of rhodopsin into both RGCs and inner nuclear layer neurons generated reproducible responses to light pulses a

    Modification:

    Article Title: Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin
    Article Snippet: carefully regulated so as to not saturate the cell response, which could cause failure of the cells to follow high frequency stimulation [ 18 , 19 ]. .. Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [ 20 ] for treatment of RP from the Univ. of Manchester [ 21 ], which promises to have higher sensitivity than ChR2 variants. .. In their study, AAV-mediated expression of rhodopsin into both RGCs and inner nuclear layer neurons generated reproducible responses to light pulses a

    Article Title: Retinal Gene Therapy
    Article Snippet: be carefully regulated so as to not saturate the cell response, which could cause failure of the cells to follow high frequency stimulation [18, 19]. .. Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [20] for treatment of RP from the Univ. of Manchester [21], which promises to have higher sensitivity than ChR2 variants. .. In their study, AAV-mediated expression of rhodopsin into both RGCs and inner nuclear layer neurons generated reproducible responses to light pulses a



    Similar Products

    human rhodopsin based optogenetic gene therapy  (Acucela Inc)
    90
    Acucela Inc human rhodopsin based optogenetic gene therapy
    Comparison of the light sensitivities of natural and artificial photoreceptor systems. Rod and cone photoreceptor sensitivities and melanopsin-expressing retinal ganglion cell sensitivity are compared with those of halorhodopsin (NpHR), wild-type channelrhodopsin 2 (ChR2), and vertebrate rhodopsin installed in various cell types. Light sensitivities are given in photons/cm2 s The wavelengths for the respective therapeutic approaches are color-coded and indicated as numbers in white. All <t>optogenetic</t> channel light sensitivities are based on in vitro retinal whole-mount recordings from retinal ganglion cells (Figure modified from [27])
    Human Rhodopsin Based Optogenetic Gene Therapy, supplied by Acucela Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+rhodopsin+based+optogenetic+gene+therapy/human+rhodopsin+based+optogenetic+gene+therapy/pmc07307607-50-6-1
    Average 90 stars, based on 1 article reviews
    human rhodopsin based optogenetic gene therapy - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Comparison of the light sensitivities of natural and artificial photoreceptor systems. Rod and cone photoreceptor sensitivities and melanopsin-expressing retinal ganglion cell sensitivity are compared with those of halorhodopsin (NpHR), wild-type channelrhodopsin 2 (ChR2), and vertebrate rhodopsin installed in various cell types. Light sensitivities are given in photons/cm2 s The wavelengths for the respective therapeutic approaches are color-coded and indicated as numbers in white. All optogenetic channel light sensitivities are based on in vitro retinal whole-mount recordings from retinal ganglion cells (Figure modified from [27])

    Journal: Methods in molecular biology (Clifton, N.J.)

    Article Title: Optogenetic Retinal Gene Therapy with the Light Gated GPCR Vertebrate Rhodopsin

    doi: 10.1007/978-1-4939-7522-8_12

    Figure Lengend Snippet: Comparison of the light sensitivities of natural and artificial photoreceptor systems. Rod and cone photoreceptor sensitivities and melanopsin-expressing retinal ganglion cell sensitivity are compared with those of halorhodopsin (NpHR), wild-type channelrhodopsin 2 (ChR2), and vertebrate rhodopsin installed in various cell types. Light sensitivities are given in photons/cm2 s The wavelengths for the respective therapeutic approaches are color-coded and indicated as numbers in white. All optogenetic channel light sensitivities are based on in vitro retinal whole-mount recordings from retinal ganglion cells (Figure modified from [27])

    Article Snippet: Recently, Acucela, Inc. has licensed a human rhodopsin based optogenetic gene therapy [ 20 ] for treatment of RP from the Univ. of Manchester [ 21 ], which promises to have higher sensitivity than ChR2 variants.

    Techniques: Comparison, Expressing, In Vitro, Modification